Lyell Immunopharma's top three insider shareholders as of April 17, 2026 are Hans Edgar Bishop (Director, 4.69Mn shares), Venture Partners Ix, Llc Arch (TenPercentOwner, 1.43Mn shares), Venture Fund Xiii, L.P. Arch (TenPercentOwner, 1.43Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Hans Edgar Bishop | - | 4,685,614 | 0 | 09 Sep, 2022 |
| Venture Partners Ix, Llc Arch | - | 0 | 1,426,528 | 09 Mar, 2026 |
| Venture Fund Xiii, L.P. Arch | - | 0 | 1,426,528 | 09 Mar, 2026 |
| Venture Partners Ix, Llc Arch | - | 0 | 1,426,528 | 09 Mar, 2026 |
| Richard Klausner | - | 0 | 930,880 | 17 Aug, 2023 |
| Richard Klausner | - | 0 | 843,365 | 18 Mar, 2025 |
| Cathy Friedman | - | 0 | 236,370 | 14 Dec, 2021 |
| Sumant Ramachandra | - | 0 | 200,000 | 25 Mar, 2025 |
| Charles W. Newton | Chief Financial Officer | 0 | 200,000 | 18 Mar, 2025 |
| Matthew Lang | Chief Business Officer | 162,500 | 0 | 26 Feb, 2025 |
| Lynn Seely | President And Ceo | 74,266 | 0 | 12 Feb, 2026 |
| Otis W Brawley | - | 35,640 | 0 | 02 Apr, 2025 |
| David Shook | Chief Medical Officer | 21,900 | 0 | 11 Jun, 2025 |
| Stephen J. Hill | Chief Operating Officer | 17,795 | 0 | 12 Feb, 2026 |
| Gary K. Lee | Chief Scientific Officer | 16,938 | 0 | 12 Feb, 2026 |
| Veronica Sanchez Bulis | Vp, Corporate Controller | 15,637 | 0 | 11 Feb, 2026 |
| Charles W. Newton | Chief Financial Officer | 15,306 | 0 | 22 Aug, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 09 Mar, 2026 | Smital Shah | Option (right to buy) | A | 140,000 | $0.00 | 140,000 | D | A |
| 06 Mar, 2026 | Venture Partners Ix, Llc Arch | Common Stock | A | 488,090 | $25.61 | 1,426,528 | I | P |
| 06 Mar, 2026 | Venture Fund Xiii, L.P. Arch | Common Stock | A | 488,090 | $25.61 | 1,426,528 | I | P |
| 11 Feb, 2026 | Lynn Seely | Common Stock | D | 7,455 | $23.39 | 74,266 | D | S |
| 11 Feb, 2026 | Stephen J. Hill | Common Stock | D | 1,236 | $23.39 | 17,795 | D | S |
| 11 Feb, 2026 | Gary K. Lee | Common Stock | D | 1,671 | $23.39 | 16,938 | D | S |
| 09 Feb, 2026 | Stephen J. Hill | Common Stock | A | 4,000 | $0.00 | 19,140 | D | A |
| 10 Feb, 2026 | Mark A Meltz | Option (right to buy) | A | 50,000 | $0.00 | 50,000 | D | A |
| 10 Feb, 2026 | Veronica Sanchez Bulis | Common Stock | A | 8,750 | $0.00 | 15,891 | D | A |
| 09 Feb, 2026 | Gary K. Lee | Common Stock | A | 4,000 | $0.00 | 18,756 | D | A |
| 09 Feb, 2026 | Lynn Seely | Common Stock | A | 20,000 | $0.00 | 82,159 | D | A |
| 10 Feb, 2026 | Veronica Sanchez Bulis | Common Stock | D | 254 | $23.12 | 15,637 | D | S |
| 10 Feb, 2026 | Gary K. Lee | Common Stock | D | 147 | $23.12 | 18,609 | D | S |
| 10 Feb, 2026 | David Shook | Option (right to buy) | A | 50,000 | $0.00 | 50,000 | D | A |
| 10 Feb, 2026 | Stephen J. Hill | Common Stock | D | 109 | $23.12 | 19,031 | D | S |
| 10 Feb, 2026 | Lynn Seely | Common Stock | D | 438 | $23.12 | 81,721 | D | S |
| 10 Feb, 2026 | Lynn Seely | Option (right to buy) | A | 155,000 | $0.00 | 155,000 | D | A |
| 10 Feb, 2026 | Gary K. Lee | Option (right to buy) | A | 50,000 | $0.00 | 50,000 | D | A |
| 10 Feb, 2026 | Stephen J. Hill | Option (right to buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 24 Dec, 2025 | Veronica Sanchez Bulis | Common Stock | D | 1,136 | $38.67 | 8,077 | D | S |